PT  - JOURNAL ARTICLE
AU  - De Silva, Kushan
AU  - Demmer, Ryan T.
AU  - Jönsson, Daniel
AU  - Mousa, Aya
AU  - Forbes, Andrew
AU  - Enticott, Joanne
TI  - Marker genes of incident type 1 diabetes in peripheral blood mononuclear cells of children: A machine learning strategy for large-p, small-n scenarios
AID  - 10.1101/2022.02.07.22270652
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.02.07.22270652
4099  - http://medrxiv.org/content/early/2022/02/09/2022.02.07.22270652.short
4100  - http://medrxiv.org/content/early/2022/02/09/2022.02.07.22270652.full
AB  - Background and objective Type 1 diabetes (TID) is a complex, polygenic disorder, the etiology of which is not fully elucidated. Machine learning (ML) genomics could provide novel insights on disease dynamics while high-dimensionality remains a challenge. This study aimed to identify marker genes of incident T1D in peripheral blood mononuclear cells (PBMC) of children via a ML strategy attuned to high-dimensionality.Methods Using samples from 105 children (81 with incident T1D and 24 healthy controls), we analyzed microarray transcriptomics via a workflow consisting of three sequential steps: application of dimension reduction strategies on the processed transcriptome; ML on the reduced gene expression matrix; and downstream network analyses to demarcate seed nodes (statistically significant genes) and hub genes. Sixteen dimension-reduction algorithms belonging to three groups (3 tailored; 3 regularizations; 10 classic) were applied. Four ML algorithms (multivariate adaptive regression splines, adaptive boosting, random forests, XGB-DART) were trained on the reduced feature set and internally-validated using repeated, 10-fold cross-validation. Marker genes were determined via variable importance metrics. Seed nodes were identified by the ‘OmicsNet’ platform while nodes having above average betweenness, closeness, and degree in the network were demarcated as hub genes.Results The processed gene expression matrix comprised 13515 genes which was reduced to contain 1003 genes collectively selected by dimension reduction algorithms. All four ML algorithms on this reduced feature set attained perfect and uniform predictive performance on internal validation. On removal of redundancies, variable importance metrics identified 30 marker genes of incident T1D in this cohort, while Early Growth Response 2 (EGR2) was uniformly selected by all four ML algorithms as the most important marker gene. Network analyses classified all 30 marker genes as seed nodes. Additionally, we identified 14 hub genes, 7 of which were found to be marker genes of incident T1D elucidated by ML.Conclusions We identified marker genes of incident T1D in PBMC of children via a ML analytic strategy attuned to the high dimensional structure of microarrays, with downstream analyses providing high biological plausibility. The demonstrated ML strategy would be useful in analyzing other high-dimensional biomedical data for biomarker discovery.Competing Interest StatementThe authors have declared no competing interest.Funding StatementKDS is supported by a PhD scholarship funded by the Australian Government under Research Training Program (RTP).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data used in this study are openly and freely available at the National Center for Biotechnology Information Gene Expression Omnibus (NCBI GEO) portal (https://www.ncbi.nlm.nih.gov/geo/), with the unique GEO accession ID of GSE9006.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in this study are freely available at the National Center for Biotechnology Information Gene Expression Omnibus (NCBI GEO) portal (https://www.ncbi.nlm.nih.gov/geo/), with the unique GEO accession ID of GSE9006.